Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

This study evaluated the efficacy and safety of once weekly semaglutide (2.4 mg) in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes. In a randomized, double blind, placebo controlled trial involving 616 participants, semaglutide significantly improved heart failure related symptoms and physical limitations (measured by KCCQ-CSS) and resulted in greater weight loss compared to placebo at 52 weeks. Secondary outcomes, including improvements in 6 minute walk distance and reductions in CRP levels, also favored semaglutide. The treatment was well tolerated, with fewer serious adverse events in the semaglutide group. These findings suggest semaglutide as a promising therapy for this high symptom burden population.

This study evaluated the efficacy and safety of once weekly semaglutide (2.4 mg) in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes. In a randomized, double blind, placebo controlled trial involving 616 participants, semaglutide significantly improved heart failure related symptoms and physical limitations (measured by KCCQ-CSS) and resulted in greater weight loss compared to placebo at 52 weeks. Secondary outcomes, including improvements in 6 minute walk distance and reductions in CRP levels, also favored semaglutide. The treatment was well tolerated, with fewer serious adverse events in the semaglutide group. These findings suggest semaglutide as a promising therapy for this high symptom burden population.